Axovant to Present at First Annual Roivant Pipeline Day

From Startup Axovant

Link to Full Article: http://investors.axovant.com/news-releases/news-release-details/axovant-present-first-annual-roivant-pipeline-day

BASEL, Switzerland, June 18, 2018 (GLOBE NEWSWIRE) — Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET.
A live webcast will be available in the Investors section of Axovant’s website at www.axovant.com. A replay will be available for 30 days following the conference.
About Roivant Pipeline Day
Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City. The event will feature presentations, fireside chats, and Q&A sessions from executives across the Roivant family of companies. The event is scheduled to begin at 2:00 p.m. ET and will continue until approximately 5:30 p.m. ET. Due to limited capacity, attendance is by invitation only but a live webcast will be available to interested parties. To request access to the webcast or to learn more about the event, please email pipelineday@roivant.com.
About Axovant Sciences
Axovant is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics in the fields of neurology and psychiatry. We are developing a pipeline of clinical and nonclinical product candidates that focuses on the various aspects of debilitating neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Lewy body dementia, and other indications in the fields of neurology and psychiatry. Our goal is to be the leading biopharmaceutical company focused on the fields of neurology and psychiatry.
For more information, visit www.axovant.com.
Contacts:
Investors
Tricia Truehart(631) 892-7014investors@axovant.com
Media
Paul Davis(646) 495-5310media@axovant.com
SOURCE Axovant Sciences
 

Source: Axovant Sciences Ltd.

Please visit their site for more information: Axovant.com

All,Biotechnology,Healthcare News,Startup News
2018-07-13 05:26:19